We believe that human clinical samples remain the most powerful means to discover and validate a biomarker. Academic biospecimen collections, representing years of investment, are often underutilized or even dormant for a number of reasons. The existing communications gap between academia and industry makes it challenging for pharmaceutical companies to pinpoint the specific sample sources they require. Trans-Hit Bio effectively bridges that gap.

Locating banked collections, or clinical sites able to prospectively collect biospecimens, with comprehensive associated medical data may boost the number of biomarker development projects. We are convinced that this will contribute to the advancement of personalized medicine approaches that should represent major changes in the biopharmaceutical industry early in the 21st century.

In summary, our fundamental belief is that the depth of expertise and the quality standards respected by our trusted academic partners are bound to advance your research and provide you with the most reliable samples and extensively annotated data.